Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | |||
| TBC | filgrastim | Cancelled | ||||
| TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
| TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | |||
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
| TBC | risperidone | Schizophrenia, adults | Suspended |
Last Updated : April 19, 2024